secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2026-08-07T12:45:14+00:00
Accession:  0001193125-26-339292
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Q2 2026: OpEx $8.7M, R&D $4.9M; raises up to $16.5M from offering
------------------------------------------------------------------------

- Total operating expenses $8.7M in Q2 2026, down $0.3M from $9.0M in Q2 2025.
- R&D expenses $4.9M in Q2 2026, down 11% YoY on lower preclinical spend.
- G&A expenses $3.8M, up 7% YoY, driven by higher legal fees from settled patent litigation.
- Raised $4.5M upfront plus up to $12M from Series A/B warrant exercises to fund (Z)-endoxifen.
- Presented (Z)-endoxifen data at ASCO/AACR; EVANGELINE Phase 2 enrollment completed as of June 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526339292/0001193125-26-339292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526339292/atos-20260807.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-339292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer